FDA Output
FDA Output, March 2026
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in March 2026. Updated March 23.
Welcome to MyStrategist
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
Start-Ups
WhiteSwell’s Lymph-Targeted ADHF Therapy Aims for System-Wide Improvements
While diuretics act directly on the fluid-overloaded vascular compartment, WhiteSwell believes that during episodes of ADHF, to effectively restore balance, interstitial fluid must be moved out of the congested tissues. The start-up plans to accomplish this with a device called the eLym System, now being studied in a multicenter, prospective single-arm study called DELTA-HF. A companion article to "Innovating Heart Failure: Start-Ups Harness Natural Pathways."
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
Pathways’ Pick of the Week
Pathways' Pick of the Week: FDA’s Weight-Loss Tech Guidance
FDA finalizes weight-loss tech guide and plans new adverse event database. Excerpted from Pathways’ Picks March 18: MDR Discussions, EtO Revisions, and More Medtech Policy Updates.